Jason Gien
Concepts (328)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernias, Diaphragmatic, Congenital | 39 | 2026 | 219 | 9.640 |
Why?
| | Extracorporeal Membrane Oxygenation | 20 | 2026 | 383 | 3.180 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 865 | 2.030 |
Why?
| | Hypertension, Pulmonary | 16 | 2022 | 1980 | 1.850 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2023 | 410 | 1.680 |
Why?
| | Persistent Fetal Circulation Syndrome | 7 | 2016 | 138 | 1.530 |
Why?
| | rho-Associated Kinases | 5 | 2016 | 83 | 1.510 |
Why?
| | Infant, Newborn | 50 | 2026 | 6429 | 1.440 |
Why?
| | Neovascularization, Physiologic | 6 | 2013 | 194 | 1.290 |
Why?
| | Pulmonary Artery | 14 | 2018 | 1134 | 1.290 |
Why?
| | Endothelin-1 | 4 | 2016 | 184 | 1.240 |
Why?
| | Endothelial Cells | 10 | 2018 | 869 | 1.150 |
Why?
| | Nitric Oxide | 8 | 2020 | 897 | 1.150 |
Why?
| | Tracheostomy | 5 | 2016 | 142 | 0.950 |
Why?
| | Lung | 16 | 2024 | 4109 | 0.920 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2023 | 41 | 0.830 |
Why?
| | Ostomy | 1 | 2023 | 3 | 0.820 |
Why?
| | Respiration, Artificial | 5 | 2025 | 708 | 0.810 |
Why?
| | PPAR gamma | 2 | 2013 | 176 | 0.750 |
Why?
| | Infant | 24 | 2023 | 10034 | 0.750 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.720 |
Why?
| | Sheep | 14 | 2018 | 880 | 0.720 |
Why?
| | Prenatal Diagnosis | 4 | 2026 | 195 | 0.720 |
Why?
| | Length of Stay | 8 | 2025 | 1337 | 0.670 |
Why?
| | Ductus Arteriosus, Patent | 3 | 2023 | 50 | 0.670 |
Why?
| | Retrospective Studies | 37 | 2025 | 17066 | 0.670 |
Why?
| | Water-Electrolyte Imbalance | 4 | 2022 | 42 | 0.660 |
Why?
| | Patient Care Team | 3 | 2016 | 689 | 0.650 |
Why?
| | Herniorrhaphy | 4 | 2025 | 74 | 0.640 |
Why?
| | Blood Gas Analysis | 2 | 2021 | 83 | 0.630 |
Why?
| | Reperfusion Injury | 1 | 2023 | 300 | 0.630 |
Why?
| | Vasodilator Agents | 4 | 2016 | 331 | 0.610 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2023 | 557 | 0.590 |
Why?
| | Pregnancy | 23 | 2026 | 7190 | 0.590 |
Why?
| | Transportation of Patients | 1 | 2020 | 68 | 0.590 |
Why?
| | Bronchodilator Agents | 1 | 2020 | 182 | 0.580 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 326 | 0.570 |
Why?
| | Shock, Septic | 1 | 2020 | 216 | 0.540 |
Why?
| | Continuity of Patient Care | 2 | 2016 | 291 | 0.500 |
Why?
| | Humans | 65 | 2026 | 144759 | 0.470 |
Why?
| | Ultrasonography, Prenatal | 4 | 2025 | 294 | 0.470 |
Why?
| | Ventilator Weaning | 1 | 2016 | 39 | 0.470 |
Why?
| | Trachea | 1 | 2018 | 261 | 0.460 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2015 | 266 | 0.450 |
Why?
| | Umbilical Arteries | 1 | 2015 | 52 | 0.450 |
Why?
| | Radial Artery | 1 | 2015 | 70 | 0.450 |
Why?
| | Hemodynamics | 4 | 2022 | 1121 | 0.450 |
Why?
| | Vasoconstrictor Agents | 2 | 2018 | 144 | 0.430 |
Why?
| | Sepsis | 2 | 2020 | 640 | 0.420 |
Why?
| | Infant, Premature | 10 | 2023 | 611 | 0.420 |
Why?
| | Female | 46 | 2026 | 78271 | 0.410 |
Why?
| | Infant, Extremely Premature | 1 | 2014 | 67 | 0.410 |
Why?
| | Vasopressins | 1 | 2014 | 60 | 0.410 |
Why?
| | Central Nervous System Diseases | 1 | 2014 | 74 | 0.400 |
Why?
| | Magnetic Resonance Imaging | 6 | 2025 | 3863 | 0.400 |
Why?
| | Hypotension | 1 | 2014 | 126 | 0.390 |
Why?
| | Weight Gain | 1 | 2017 | 556 | 0.380 |
Why?
| | Hernia, Diaphragmatic | 3 | 2021 | 67 | 0.380 |
Why?
| | Patient Discharge | 4 | 2021 | 983 | 0.370 |
Why?
| | Oxygen Consumption | 1 | 2015 | 724 | 0.370 |
Why?
| | Echocardiography | 5 | 2023 | 652 | 0.360 |
Why?
| | Hospital Mortality | 3 | 2021 | 1030 | 0.360 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1560 | 0.350 |
Why?
| | Gastrostomy | 3 | 2023 | 130 | 0.350 |
Why?
| | Developmental Disabilities | 1 | 2014 | 281 | 0.340 |
Why?
| | Enzyme Activation | 1 | 2012 | 766 | 0.340 |
Why?
| | Animals, Newborn | 5 | 2023 | 902 | 0.310 |
Why?
| | Communication | 1 | 2016 | 965 | 0.300 |
Why?
| | Pulmonary Alveoli | 4 | 2014 | 383 | 0.290 |
Why?
| | Endothelium, Vascular | 3 | 2013 | 965 | 0.280 |
Why?
| | Bacteremia | 3 | 2019 | 221 | 0.270 |
Why?
| | Kidney | 6 | 2023 | 1495 | 0.270 |
Why?
| | Lung Volume Measurements | 3 | 2023 | 46 | 0.270 |
Why?
| | Cardiopulmonary Resuscitation | 2 | 2022 | 340 | 0.260 |
Why?
| | Survival Rate | 4 | 2022 | 2089 | 0.250 |
Why?
| | Sulfonamides | 3 | 2016 | 580 | 0.250 |
Why?
| | Animals | 18 | 2023 | 38058 | 0.240 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2022 | 392 | 0.240 |
Why?
| | Fetal Growth Retardation | 3 | 2018 | 587 | 0.240 |
Why?
| | Morbidity | 2 | 2023 | 323 | 0.230 |
Why?
| | Male | 27 | 2025 | 72315 | 0.230 |
Why?
| | Fetal Diseases | 1 | 2007 | 191 | 0.230 |
Why?
| | Severity of Illness Index | 6 | 2025 | 2925 | 0.230 |
Why?
| | Receptors, Endothelin | 2 | 2016 | 50 | 0.220 |
Why?
| | Cells, Cultured | 8 | 2014 | 4154 | 0.220 |
Why?
| | Risk Factors | 9 | 2021 | 10779 | 0.220 |
Why?
| | Hirudins | 1 | 2024 | 51 | 0.210 |
Why?
| | Fetus | 6 | 2023 | 803 | 0.210 |
Why?
| | Urinary Tract Infections | 4 | 2019 | 202 | 0.210 |
Why?
| | Antithrombins | 1 | 2024 | 70 | 0.210 |
Why?
| | Treatment Outcome | 8 | 2025 | 11679 | 0.210 |
Why?
| | Signal Transduction | 6 | 2018 | 5226 | 0.210 |
Why?
| | Endotoxins | 2 | 2015 | 221 | 0.200 |
Why?
| | Renal Replacement Therapy | 2 | 2022 | 100 | 0.200 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 104 | 0.200 |
Why?
| | Hernia, Umbilical | 1 | 2023 | 21 | 0.200 |
Why?
| | Pulmonary Veins | 2 | 2014 | 105 | 0.200 |
Why?
| | Nitric Oxide Synthase Type III | 4 | 2013 | 204 | 0.200 |
Why?
| | Heparin | 1 | 2024 | 244 | 0.190 |
Why?
| | Fundoplication | 2 | 2020 | 54 | 0.190 |
Why?
| | Umbilical Cord | 1 | 2023 | 91 | 0.190 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2115 | 0.190 |
Why?
| | Pulmonary Circulation | 4 | 2014 | 430 | 0.190 |
Why?
| | Parturition | 1 | 2023 | 69 | 0.180 |
Why?
| | Tracheobronchomalacia | 1 | 2022 | 15 | 0.180 |
Why?
| | Surgical Flaps | 2 | 2023 | 142 | 0.180 |
Why?
| | Fetal Blood | 1 | 2024 | 342 | 0.180 |
Why?
| | Tracheomalacia | 1 | 2022 | 17 | 0.180 |
Why?
| | Biomarkers | 3 | 2024 | 4271 | 0.180 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 38 | 0.180 |
Why?
| | Gestational Age | 7 | 2021 | 975 | 0.180 |
Why?
| | Peptide Fragments | 1 | 2024 | 699 | 0.160 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 51 | 0.160 |
Why?
| | Guanylate Cyclase | 2 | 2011 | 39 | 0.160 |
Why?
| | Interactive Ventilatory Support | 1 | 2020 | 2 | 0.160 |
Why?
| | Benzoates | 2 | 2011 | 50 | 0.160 |
Why?
| | Analgesia | 1 | 2021 | 105 | 0.160 |
Why?
| | Serotonin | 2 | 2013 | 293 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 478 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 64 | 0.150 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1907 | 0.150 |
Why?
| | Infant Mortality | 2 | 2019 | 123 | 0.150 |
Why?
| | Anticoagulants | 1 | 2024 | 722 | 0.150 |
Why?
| | Prospective Studies | 5 | 2024 | 7990 | 0.150 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 2016 | 28 | 0.150 |
Why?
| | Thrombelastography | 1 | 2020 | 178 | 0.150 |
Why?
| | Heart Atria | 1 | 2020 | 144 | 0.150 |
Why?
| | Diuretics | 2 | 2018 | 68 | 0.140 |
Why?
| | Rats | 4 | 2023 | 5597 | 0.140 |
Why?
| | Heart Failure | 2 | 2022 | 2323 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 209 | 0.140 |
Why?
| | Asphyxia Neonatorum | 1 | 2018 | 18 | 0.140 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2018 | 22 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 189 | 0.140 |
Why?
| | MicroRNAs | 1 | 2024 | 701 | 0.140 |
Why?
| | Cell Proliferation | 3 | 2015 | 2496 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 85 | 0.130 |
Why?
| | Child | 8 | 2022 | 22633 | 0.130 |
Why?
| | Administration, Inhalation | 2 | 2016 | 574 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2015 | 4557 | 0.130 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 289 | 0.130 |
Why?
| | Blood Vessels | 2 | 2016 | 171 | 0.130 |
Why?
| | Survival Analysis | 2 | 2020 | 1382 | 0.130 |
Why?
| | Intensive Care Units, Neonatal | 5 | 2018 | 279 | 0.130 |
Why?
| | Brain Diseases | 1 | 2018 | 152 | 0.130 |
Why?
| | Injections, Intraperitoneal | 1 | 2016 | 116 | 0.120 |
Why?
| | Infant Care | 1 | 2016 | 44 | 0.120 |
Why?
| | Expectorants | 1 | 2016 | 23 | 0.120 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 75 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 3 | 2016 | 2527 | 0.120 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2016 | 150 | 0.120 |
Why?
| | Ventilators, Mechanical | 1 | 2016 | 70 | 0.120 |
Why?
| | Bacterial Infections | 1 | 2018 | 246 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.120 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 370 | 0.120 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 18 | 0.120 |
Why?
| | Steroids | 1 | 2016 | 160 | 0.110 |
Why?
| | Cross Infection | 1 | 2018 | 262 | 0.110 |
Why?
| | Receptors, Calcitriol | 1 | 2015 | 55 | 0.110 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 45 | 0.110 |
Why?
| | Bleomycin | 1 | 2016 | 253 | 0.110 |
Why?
| | Preoperative Care | 1 | 2017 | 379 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 217 | 0.110 |
Why?
| | Intubation, Intratracheal | 1 | 2018 | 320 | 0.110 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 275 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2024 | 3604 | 0.110 |
Why?
| | Catalase | 1 | 2015 | 130 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 269 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 284 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 1 | 2015 | 92 | 0.110 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 49 | 0.110 |
Why?
| | Databases, Factual | 5 | 2018 | 1486 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 97 | 0.110 |
Why?
| | Arteriovenous Fistula | 1 | 2014 | 38 | 0.100 |
Why?
| | Cyclic GMP | 2 | 2011 | 92 | 0.100 |
Why?
| | Coculture Techniques | 1 | 2015 | 246 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.100 |
Why?
| | Positive-Pressure Respiration | 1 | 2015 | 112 | 0.100 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2013 | 62 | 0.100 |
Why?
| | Capillaries | 1 | 2014 | 124 | 0.100 |
Why?
| | Logistic Models | 4 | 2020 | 2117 | 0.100 |
Why?
| | Pregnancy Trimester, Third | 2 | 2024 | 115 | 0.100 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2013 | 18 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 301 | 0.090 |
Why?
| | Ligation | 1 | 2012 | 92 | 0.090 |
Why?
| | Ductus Arteriosus | 1 | 2012 | 72 | 0.090 |
Why?
| | Vitamins | 1 | 2014 | 178 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1716 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 635 | 0.090 |
Why?
| | Diaphragm | 2 | 2023 | 49 | 0.090 |
Why?
| | Amides | 1 | 2012 | 101 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 341 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 621 | 0.090 |
Why?
| | DNA Primers | 1 | 2012 | 512 | 0.090 |
Why?
| | Hospitalization | 2 | 2021 | 2433 | 0.090 |
Why?
| | Pyridines | 2 | 2012 | 605 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1047 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.080 |
Why?
| | Isoenzymes | 1 | 2011 | 299 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 905 | 0.080 |
Why?
| | Vitamin D | 1 | 2014 | 400 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2273 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1187 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 178 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1306 | 0.080 |
Why?
| | Amniotic Fluid | 2 | 2024 | 79 | 0.080 |
Why?
| | Vasodilation | 2 | 2011 | 523 | 0.070 |
Why?
| | Prognosis | 3 | 2023 | 4282 | 0.070 |
Why?
| | Myosin-Light-Chain Phosphatase | 1 | 2008 | 2 | 0.070 |
Why?
| | Hypoxia | 1 | 2016 | 1199 | 0.070 |
Why?
| | Dipeptides | 1 | 2008 | 57 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2023 | 338 | 0.070 |
Why?
| | Nitroarginine | 1 | 2007 | 57 | 0.070 |
Why?
| | Phosphorylation | 2 | 2011 | 1732 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2009 | 824 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2879 | 0.060 |
Why?
| | Blood Pressure | 1 | 2014 | 1769 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1289 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 235 | 0.060 |
Why?
| | Oxadiazoles | 3 | 2011 | 37 | 0.060 |
Why?
| | Pilot Projects | 2 | 2024 | 1886 | 0.060 |
Why?
| | Vascular Resistance | 3 | 2013 | 367 | 0.060 |
Why?
| | Fetoscopy | 1 | 2026 | 33 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2017 | 2919 | 0.060 |
Why?
| | Pulmonary Edema | 1 | 2006 | 106 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 766 | 0.060 |
Why?
| | Hyperoxia | 1 | 2006 | 99 | 0.060 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 556 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1370 | 0.050 |
Why?
| | Child, Preschool | 2 | 2020 | 11787 | 0.050 |
Why?
| | Odds Ratio | 2 | 2018 | 1075 | 0.050 |
Why?
| | Cell Membrane | 1 | 2008 | 706 | 0.050 |
Why?
| | Phenotype | 2 | 2016 | 3162 | 0.050 |
Why?
| | Fetal Development | 1 | 2007 | 299 | 0.050 |
Why?
| | Indomethacin | 1 | 2023 | 76 | 0.050 |
Why?
| | Liver | 2 | 2022 | 1887 | 0.050 |
Why?
| | Adult | 4 | 2024 | 40449 | 0.050 |
Why?
| | Ketanserin | 2 | 2013 | 12 | 0.050 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.050 |
Why?
| | Sertraline | 2 | 2013 | 27 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1813 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2022 | 36 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 506 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 16 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 65 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 167 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 9 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3671 | 0.040 |
Why?
| | Intubation | 1 | 2018 | 7 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 223 | 0.040 |
Why?
| | Oligohydramnios | 1 | 2018 | 12 | 0.040 |
Why?
| | Polyhydramnios | 1 | 2018 | 17 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 216 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 14105 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2022 | 560 | 0.040 |
Why?
| | Apgar Score | 1 | 2018 | 20 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 189 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 42 | 0.040 |
Why?
| | Heart | 1 | 2022 | 636 | 0.030 |
Why?
| | Surgical Mesh | 1 | 2018 | 50 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2018 | 122 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 166 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 7173 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 104 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 153 | 0.030 |
Why?
| | Pneumonia | 2 | 2018 | 631 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 285 | 0.030 |
Why?
| | Gene Expression | 2 | 2013 | 1490 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 561 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 551 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 144 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 136 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 2018 | 122 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 541 | 0.030 |
Why?
| | Adolescent | 1 | 2016 | 22428 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1135 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 282 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2027 | 0.030 |
Why?
| | Postpartum Period | 1 | 2019 | 365 | 0.030 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 129 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2015 | 16 | 0.030 |
Why?
| | Calcifediol | 1 | 2015 | 31 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2016 | 85 | 0.030 |
Why?
| | Birth Weight | 1 | 2018 | 522 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 455 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2020 | 760 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 854 | 0.030 |
Why?
| | United States | 3 | 2018 | 15966 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 863 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 220 | 0.030 |
Why?
| | Sheep, Domestic | 1 | 2013 | 33 | 0.020 |
Why?
| | Tryptophan Hydroxylase | 1 | 2013 | 54 | 0.020 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 182 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2013 | 197 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1143 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1539 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3333 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 9 | 0.020 |
Why?
| | Cell Aggregation | 1 | 2011 | 19 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 35 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 72 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2011 | 94 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 85 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 54 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 173 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5960 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 645 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 914 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 247 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 336 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2385 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1720 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 436 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 67 | 0.020 |
Why?
| | Piperazines | 1 | 2011 | 381 | 0.020 |
Why?
| | Acetylcholine | 1 | 2009 | 204 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 995 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2834 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 501 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 965 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2009 | 452 | 0.020 |
Why?
| | Organ Size | 1 | 2006 | 463 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 976 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2507 | 0.010 |
Why?
|
|
Gien's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|